Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRRA: Mepolizumab in EGPA
NCT02020889Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by GSK. Started Feb 2014; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT02020889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020889.